Sembolic/ Semalix
by Torrent Pharmaceuticals · DCGI approved 2025
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Torrent Pharmaceuticals Ltd |
| DCGI status | Approved 2025 |
| Price (MRP) | TBC (price band to be announced) |
| Format | Injectable + Oral Injectable via Zydus license · Oral tablets (3 mg, 7 mg, 14 mg) |
| Prescription | Schedule H — required |
How Sembolic compares
Sembolic is Torrent's brand of generic semaglutide and one of the few Indian launches to cover both injectable and oral formats. The injectable uses the Zydus reusable-pen platform under licence; the oral tablets are a generic equivalent of Novo Nordisk's Rybelsus. Sister brand Semalix runs in parallel commercial channels. Final pricing has not yet been published.
About Torrent Pharmaceuticals
Torrent Pharmaceuticals is one of India's top-fifteen pharma companies with a strong franchise in cardiology and gastroenterology. Co-marketing semaglutide via the Zydus device platform accelerates time-to-market while leveraging Torrent's specialist distribution.
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.